- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
An article published in the Lancet states that Sinovac Biotech's 'CoronaVac' vaccine triggered a “quick immune response.” These findings are based on the Phase 1 & 2 trials conducted in April and May of this year. The article discusses that this property may make the vaccine "suitable for emergency use".
Trials of the Sinovac Biotech vaccine in Brazil were briefly halted last week but resumed after the reported death of a volunteer was found to have no links to the vaccine.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
